Heterologous expression and characterization of plant Taxadiene-5α-Hydroxylase (CYP725A4) in Escherichia coli

Protein Expression and Purification

Volumn 132, Issue , 2017, Pages 60-67

  Rouck, John Edward ^a   Biggs, Bradley Walters ^b,c   Kambalyal, Amogh ^a   Arnold, William R ^a   De Mey, Marjan ^d   Ajikumar, Parayil Kumaran ^b   Das, Aditi ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b Manus Biosynthesis   (United States)

^c Northwestern University   (United States)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

E. coli; Nanodiscs; Recombinant expression; Taxadiene; Taxadiene 5 ol

Indexed keywords

ALKENE; CYTOCHROME P450; DITERPENE; PLANT PROTEIN; RECOMBINANT PROTEIN; TAXA-4(5),11(12)DIENE;

BINDING SITE; BIOSYNTHESIS; CHEMISTRY; ENZYMOLOGY; ESCHERICHIA COLI; GENETICS; ISOLATION AND PURIFICATION; KINETICS; METABOLISM; TAXUS;

ALKENES; BINDING SITES; CYTOCHROME P-450 ENZYME SYSTEM; DITERPENES; ESCHERICHIA COLI; KINETICS; PLANT PROTEINS; RECOMBINANT PROTEINS; TAXUS;

EID: 85010637436     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2017.01.008     Document Type: Article

References (48)

1. [1] Hefner, J., et al. Cytochrome P450-catalyzed hydroxylation of taxa-4(5),11(12)-diene to taxa-4(20),11(12)-dien-5alpha-ol: the first oxygenation step in taxol biosynthesis. Chem. Biol. 3:6 (1996), 479–489.
2. [2] Li, H., et al. Studies on taxol biosynthesis: preparation of taxadiene-diol- and triol-derivatives by deoxygenation of taxusin. Tetrahedron 64:27 (2008), 6561–6567.
3. [3] Lokeshwar, B.L., Ferrell, S.M., Block, N.L., Enhancement of radiation response of prostatic carcinoma by taxol: therapeutic potential for late-stage malignancy. Anticancer Res. 15:1 (1995), 93–98.
4. [4] Xu, P., Bhan, N., Koffas, M.A.G., Engineering plant metabolism into microbes: from systems biology to synthetic biology. Curr. Opin. Biotechnol. 24:2 (2013), 291–299.
5. [5] Marienhagen, J., Bott, M., Metabolic engineering of microorganisms for the synthesis of plant natural products. J. Biotechnol. 163:2 (2013), 166–178.
6. [6] Keasling, J.D., Mendoza, A., Baran, P.S., Synthesis: a constructive debate. Nature 492:7428 (2012), 188–189.
7. [7] Keasling, J.D., Manufacturing molecules through metabolic engineering. Science 330:6009 (2010), 1355–1358.
8. [8] Pickens, L.B., Tang, Y., Chooi, Y.-H., Metabolic engineering for the production of natural products. Annu. Rev. Chem. Biomol. Eng. 2 (2011), 211–236.
9. [9] Ajikumar, P.K., et al. Isoprenoid pathway optimization for Taxol precursor overproduction in Escherichia coli. Science 330:6000 (2010), 70–74.
10. [10] Biggs, B.W., et al. Overcoming heterologous protein interdependency to optimize P450-mediated Taxol precursor synthesis in Escherichia coli. Proc. Natl. Acad. Sci. 113:12 (2016), 3209–3214.
11. [11] Jennewein, S., et al. Cytochrome p450 taxadiene 5alpha-hydroxylase, a mechanistically unusual monooxygenase catalyzing the first oxygenation step of taxol biosynthesis. Chem. Biol. 11:3 (2004), 379–387.
12. [12] Rontein, D., et al. CYP725A4 from yew catalyzes complex structural rearrangement of taxa-4(5),11(12)-diene into the cyclic ether 5(12)-oxa-3(11)-cyclotaxane. J. Biol. Chem. 283:10 (2008), 6067–6075.
13. [13] Yadav, V.G., Unraveling the multispecificity and catalytic promiscuity of taxadiene monooxygenase. J. Mol. Catal. B Enzym. 110:0 (2014), 154–164.
14. [14] Edgar, S., et al. Mechanistic insights into taxadiene epoxidation by taxadiene-5α-hydroxylase. ACS Chem. Biol., 11(2), 2015, 460–469.
15. [15] Barton, N.A., et al. Accessing low-oxidation state taxanes: is taxadiene-4(5)-epoxide on the taxol biosynthetic pathway?. Chem. Sci. 7 (2016), 3102–3107.
16. [16] Biggs, B.W., et al. Orthogonal assays clarify the oxidative biochemistry of Taxol P450 CYP725A4. ACS Chem. Biol. 11:5 (2016), 1445–1451.
17. [17] Zelasko, S., Palaria, A., Das, A., Optimizations to achieve high-level expression of cytochrome P450 proteins using Escherichia coli expression systems. Protein Expr. Purif. 92:1 (2013), 77–87.
18. [18] McDougle, D.R., et al. Incorporation of charged residues in the CYP2J2 F-G loop disrupts CYP2J2-lipid bilayer interactions. Biochim. Biophys. Acta 1848:10 Pt A (2015), 2460–2470.
19. [19] McDougle, D.R., et al. Functional studies of N-terminally modified CYP2J2 epoxygenase in model lipid bilayers. Protein Sci. 22:7 (2013), 964–979.
20. [20] Hammarström, M., et al. Effect of N-terminal solubility enhancing fusion proteins on yield of purified target protein. J. Struct. Funct. Genomics 7:1 (2006), 1–14.
21. [21] Wang, M., et al. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc. Natl. Acad. Sci. U. S. A. 94:16 (1997), 8411–8416.
22. [22] Denisov, I.G., Sligar, S.G., Cytochromes P450 in nanodiscs. Biochim. Biophys. Acta 1814:1 (2011), 223–229.
23. [23] Bayburt, T.H., Sligar, S.G., Membrane protein assembly into Nanodiscs. FEBS Lett. 584:9 (2010), 1721–1727.
24. [24] Leitz, A.J., et al. Functional reconstitution of Beta2-adrenergic receptors utilizing self-assembling Nanodisc technology. Biotechniques 40:5 (2006), 601–602 604, 606, passim.
25. [25] Boldog, T., et al. Nanodiscs separate chemoreceptor oligomeric states and reveal their signaling properties. Proc. Natl. Acad. Sci. 103:31 (2006), 11509–11514.
26. [26] Nath, A., Atkins, W.M., Sligar, S.G., Applications of phospholipid bilayer nanodiscs in the study of membranes and membrane proteins. Biochemistry 46:8 (2007), 2059–2069.
27. [27] Das, A., Grinkova, Y.V., Sligar, S.G., Redox potential control by drug binding to cytochrome P450 3A4. J. Am. Chem. Soc. 129:45 (2007), 13778–13779.
28. [28] Duan, H., Schuler, M., Heterologous expression and strategies for encapsulation of membrane-localized plant P450s. Phytochem. Rev. 5:2–3 (2006), 507–523.
29. [29] Das, A., Sligar, S.G., Modulation of the cytochrome P450 reductase redox potential by the phospholipid bilayer. Biochemistry 48:51 (2009), 12104–12112.
30. [30] Bayburt, T.H., Sligar, S.G., Self-assembly of single integral membrane proteins into soluble nanoscale phospholipid bilayers. Protein Science. A Publ. Protein Soc. 12:11 (2003), 2476–2481.
31. [31] Bayburt, T.H., Sligar, S.G., Single-molecule height measurements on microsomal cytochrome P450 in nanometer-scale phospholipid bilayer disks. Proc. Natl. Acad. Sci. U. S. A. 99:10 (2002), 6725–6730.
32. [32] Civjan, N.R., et al. Direct solubilization of heterologously expressed membrane proteins by incorporation into nanoscale lipid bilayers. BioTechniques 35:3 (2003), 556–560 562-3.
33. [33] Duan, H., et al. Co-incorporation of heterologously expressed Arabidopsis cytochrome P450 and P450 reductase into soluble nanoscale lipid bilayers. Archives Biochem. Biophysics 424:2 (2004), 141–153.
34. [34] McDougle, D.R., et al. Functional studies of N-terminally modified CYP2J2 epoxygenase in model lipid bilayers. Protein Sci. 22:7 (2013), 964–979.
35. [35] Kelley, L.A., et al. The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc. 10:6 (2015), 845–858.
36. [36] Humphrey, W., Dalke, A., Schulten, K., VMD: visual molecular dynamics. J. Mol. Graph. 14:1 (1996), 33–38.
37. [37] Gonzalez, F.J., Korzekwa, K.R., Cytochromes P450 expression systems. Annu. Rev. Pharmacol. Toxicol. 35 (1995), 369–390.
38. [38] Larson, J.R., Coon, M.J., Porter, T.D., Purification and properties of a shortened form of cytochrome P-450 2E1: deletion of the NH2-terminal membrane-insertion signal peptide does not alter the catalytic activities. Proc. Natl. Acad. Sci. U. S. A. 88:20 (1991), 9141–9145.
39. [39] von Wachenfeldt, C., et al. Microsomal P450 2C3 is expressed as a soluble dimer inEscherichia coliFollowing modifications of its N-terminus. Archives Biochem. Biophysics 339:1 (1997), 107–114.
40. [40] Richardson, T.H., et al. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily inEscherichia coli. Archives Biochem. Biophysics 323:1 (1995), 87–96.
41. [41] Barnes, H.J., Arlotto, M.P., Waterman, M.R., Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 88:13 (1991), 5597–5601.
42. [42] Miki, Y., Asano, Y., Biosynthetic pathway for the cyanide-free production of phenylacetonitrile in Escherichia coli by utilizing plant cytochrome P450 79A2 and bacterial aldoxime dehydratase. Appl. Environ. Microbiol. 80:21 (2014), 6828–6836.
43. [43] Guo, Z.Y., et al. Expression of modified human cytochrome P450 1A1 in Escherichia coli: effects of 5′ substitution, stabilization, purification, spectral characterization, and catalytic properties. Archives Biochem. Biophysics 312:2 (1994), 436–446.
44. [44] Budriang, C., P.R.a.J.Y., An expression of an insect membrane-bound cytochrome P450 CYP6AA3 in the Escherichia coli in relation to insecticide resistance in a malarial vector. Pak. J. Biol. Sci. 14:8 (2011), 466–475.
45. [45] Müller, P., et al. Field-caught permethrin-resistant Anopheles gambiae overexpress CYP6P3, a P450 that metabolises pyrethroids. PLoS Genet., 4(11), 2008, e1000286.
46. [46] Larkin, M.A., et al. Clustal W and clustal X version 2.0. Bioinformatics 23:21 (2007), 2947–2948.
47. [47] Al-Gailany, K.A.S., Houston, J.B., Bridges, J.W., The role of substrate lipophilicity in determining type 1 microsomal P450 binding characteristics. Biochem. Pharmacol. 27:5 (1978), 783–788.
48. [48] Baudry, J., et al. Molecular docking of substrates and inhibitors in the catalytic site of CYP6B1, an insect cytochrome P450 monooxygenase. Protein Eng. 16:8 (2003), 577–587.